Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc.

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Latest Biotechnology and IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals, Inc. Stock News

As of July 31, 2026, IDEAYA Biosciences, Inc. had a $3.4 billion market capitalization, compared to the Biotechnology median of $252.6 million. IDEAYA Biosciences, Inc.’s stock is up 2.7% in 2026, up 0.3% in the previous five trading days and up 40.04% in the past year.

Currently, IDEAYA Biosciences, Inc. does not have a price-earnings ratio. IDEAYA Biosciences, Inc.’s trailing 12-month revenue is $225.3 million with a -62.2% net profit margin. As of July 31, 2026, IDEAYA Biosciences, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.287 per share for the current fiscal year. IDEAYA Biosciences, Inc. does not currently pay a dividend.

As of July 31, 2026, Crinetics Pharmaceuticals, Inc. had a $8.8 billion market cap, putting it in the 76th percentile of all stocks. Crinetics Pharmaceuticals, Inc.’s stock is up 79.4% in 2026, down 0.3% in the previous five trading days and up 185.73% in the past year.

Currently, Crinetics Pharmaceuticals, Inc. does not have a price-earnings ratio. Crinetics Pharmaceuticals, Inc.’s trailing 12-month revenue is $18.1 million with a % net profit margin. As of July 31, 2026, Crinetics Pharmaceuticals, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.621 per share for the current fiscal year. Crinetics Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
IDEAYA Biosciences, Inc.	IDYA	F
Crinetics Pharmaceuticals, Inc.	CRNX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

IDEAYA Biosciences, Inc. has a Value Score of 17, which is Ultra Expensive. Crinetics Pharmaceuticals, Inc. has a Value Score of 3, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals or Inc. is the better investment when it comes to value.

IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc. Growth Grades

Company	Ticker	Growth
IDEAYA Biosciences, Inc.	IDYA	F
Crinetics Pharmaceuticals, Inc.	CRNX	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

IDEAYA Biosciences, Inc. has a Growth Score of 12, which is Very Weak. Crinetics Pharmaceuticals, Inc. has a Growth Score of 12, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals or Inc. is the better investment when it comes to sustainable growth.

IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
IDEAYA Biosciences, Inc.	IDYA	D
Crinetics Pharmaceuticals, Inc.	CRNX	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

IDEAYA Biosciences, Inc. has a Earnings Estimate Score of 35, which is Negative. Crinetics Pharmaceuticals, Inc. has a Earnings Estimate Score of 58, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals or Inc. is the better investment when it comes to estimate revisions.

Other IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc. Grades

In addition to Growth, Value and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals or Inc. Stock?

Overall, IDEAYA Biosciences, Inc. stock has a Value Score of 17, Growth Score of 12 and Estimate Revisions Score of 35.

Crinetics Pharmaceuticals, Inc. stock has a Value Score of 3, Growth Score of 12 and Estimate Revisions Score of 58.

Comparing IDEAYA Biosciences, Inc., Crinetics Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.